Jun 30, 2025 • 8:00 am EDT Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Jun 25, 2025 • 8:00 am EDT Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
Jun 24, 2025 • 4:05 pm EDT Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
May 22, 2025 • 8:00 am EDT Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 19, 2025 • 8:00 am EDT Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
May 8, 2025 • 8:00 am EDT Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
May 6, 2025 • 8:00 am EDT Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Mar 28, 2025 • 8:00 am EDT Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Mar 11, 2025 • 8:00 am EDT Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update